Theradaptive

We are very excited to share a momentous achievement for Theradaptive: FDA approval to commence human clinical studies. Our journey advances with the initiation of the OASIS study, a groundbreaking Phase I/II examination of the safety and efficacy of OsteoAdapt in TLIF spinal fusion procedures.

This signifies that the remarkable product our team has dedicated extensive time and effort to is now poised for its inaugural use in treating humans. Together, we're staying true to our commitment to bring renewed hope to patients facing limited options.



https://www.prnewswire.com/news-releases/us-fda-grants-theradaptive-ide-approval-for-phase-iii-clinical-trials-302050556.html?tc=eml_cleartime

We are excited to announce that Theradaptive has been granted an additional Breakthrough Medical Device designation for Spinal Fusion by the FDA. Click here to read more:

Theradaptive Wins Additional FDA Breakthrough Designation for Spinal Fusion /PRNewswire/ -- Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug...

We are excited to announce that Theradaptive has been granted a Breakthrough Medical Device designation by the FDA. Click here to read more:

Theradaptive BizSpotlight - Boston Business Journal Discover the latest press releases from Theradaptive with the Boston Business Journal's BizSpotlight